Chiara Pozzi,Riccardo Sarti,Antonino Lo Cascio,Stefanos Bonovas,Luca Tiraboschi,Michela Lizier,Alice Bertocchi,Rosalba Torrisi,Bethania Fernandes,Piergiuseppe Colombo,Pietro Diana,Emilia Maria Cristina Mazza,Marina Valeri,Salvatore Lorenzo Renne,Ferdinando Carlo Maria Cananzi,Laura Samà,Alexia Bertuzzi,Corrado Tinterri,Massimo Lazzeri,Maria Rescigno
{"title":"PV-1:各种实体瘤远处转移的新分子预后标志物。","authors":"Chiara Pozzi,Riccardo Sarti,Antonino Lo Cascio,Stefanos Bonovas,Luca Tiraboschi,Michela Lizier,Alice Bertocchi,Rosalba Torrisi,Bethania Fernandes,Piergiuseppe Colombo,Pietro Diana,Emilia Maria Cristina Mazza,Marina Valeri,Salvatore Lorenzo Renne,Ferdinando Carlo Maria Cananzi,Laura Samà,Alexia Bertuzzi,Corrado Tinterri,Massimo Lazzeri,Maria Rescigno","doi":"10.1038/s44321-025-00277-5","DOIUrl":null,"url":null,"abstract":"Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":"6 1","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors.\",\"authors\":\"Chiara Pozzi,Riccardo Sarti,Antonino Lo Cascio,Stefanos Bonovas,Luca Tiraboschi,Michela Lizier,Alice Bertocchi,Rosalba Torrisi,Bethania Fernandes,Piergiuseppe Colombo,Pietro Diana,Emilia Maria Cristina Mazza,Marina Valeri,Salvatore Lorenzo Renne,Ferdinando Carlo Maria Cananzi,Laura Samà,Alexia Bertuzzi,Corrado Tinterri,Massimo Lazzeri,Maria Rescigno\",\"doi\":\"10.1038/s44321-025-00277-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.\",\"PeriodicalId\":11597,\"journal\":{\"name\":\"EMBO Molecular Medicine\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMBO Molecular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s44321-025-00277-5\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-025-00277-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors.
Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.
期刊介绍:
EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.
To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:
Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)